PRL-3 activates mTORC1 in Cancer Progression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Phosphatase of regenerating liver-3 (PRL-3) is implicated in cancer metastasis.
• PRL-3's oncogenic functions are linked to PI3K/Akt signaling, a regulator of mTORC1.
• A direct link between PRL-3 and mTOR activation has not been established.

Purpose of the Study:

• To investigate the relationship between PRL-3 expression and mTOR activation in cancer.
• To elucidate the mechanisms by which PRL-3 influences mTOR signaling.
• To determine the role of PRL-3-mediated mTOR activation in cancer cell invasion and survival.

Main Methods:

• Correlation analysis of PRL-3 expression and mTOR phospho-activation in clinical tumor samples and mouse models.
• Western blotting to assess downstream signaling to mTOR substrates (p70S6K, 4E-BP1).
• Investigation of PRL-3's effect on Rheb-GTP activation, TSC2 suppression, and mTOR translocation to lysosomes.
• Assessment of matrix metalloproteinase-2 secretion and cellular invasiveness, and sensitivity to rapamycin.

Main Results:

• A positive correlation was observed between PRL-3 expression and mTOR phospho-activation.
• PRL-3 enhances PI3K/Akt-mediated activation of Rheb-GTP by suppressing TSC2, leading to increased p70S6K and 4E-BP1 phosphorylation.
• PRL-3 promotes mTOR translocation to lysosomes via Akt-independent binding to Rag GTPases.
• PRL-3-induced matrix metalloproteinase-2 secretion and cellular invasiveness are dependent on mTOR activation and sensitive to rapamycin.

Conclusions:

• PRL-3 directly activates mTOR signaling through both PI3K/Akt-dependent and -independent pathways.
• PRL-3 enhances cancer cell invasion and survival by activating mTOR, providing a survival advantage under stress.
• Targeting the PRL-3-mTOR axis represents a potential therapeutic strategy for metastatic cancers.